1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Despite Trial Failure, NRx Leads In Bipolar

 
• By Elizabeth Cairns

ANALYSIS: Few companies are pursuing therapies for bipolar disorder, but the few ongoing trials will yield data very shortly.    

Two paper heads in black and white, crumbling at the top, representing bipolar disorder
• Source: Shutterstock

The failure of NRx Pharmaceuticals, Inc.’s NRX-101 in suicidal bipolar depression at the end of April highlights the difficulty of treating this intractable condition. The company is still moving forward with NRX-101, and has a Phase III trial already underway, but it has a battle on its hands. And it seems few other companies are willing to develop products specifically for bipolar depression.

Key Takeaways
  • Only a handful of innovative bipolar disorder products are in the clinic.
  • NRx Pharmaceuticals is the leading company on this measure, but has suffered a recent trial failure

In order to focus on innovative products, this analysis excludes therapies that are already approved for bipolar disorder, even if they have active trials to extend their market reach – for example pediatric

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.